Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation

Richard L Momparler1,2*, Sylvie Côté2, Louise F Momparler2 and Youssef Idaghdour3

Abstract

Background: The silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation occurs frequently in acute myeloid leukemia (AML). This epigenetic alteration can be reversed by 5-aza-2'-deoxycytidine (decitabine, 5-AZA-CdR). Although 5-AZA-CdR can induce complete remissions in patients with AML, most patients relapse. The effectiveness of this therapy may be limited by the inability of 5-AZA-CdR to reactivate all TSGs due to their silencing by other epigenetic mechanisms such as histone methylation or chromatin compaction. EZH2, a subunit of the polycomb repressive complex 2, catalyzes the methylation of histone H3 lysine 27 (H3K27) to H3K27me3. 3-Deazaneplanocin-A (DZNep), an inhibitor of methionine metabolism, can reactivate genes silenced by H3K27me3 by its inhibition of EZH2. In a previous report, we observed that 5-AZA-CdR, in combination with DZNep, shows synergistic antineoplastic action against AML cells. Gene silencing due to chromatin compaction is attributable to the action of histone deacetylases (HDAC). This mechanism of epigenetic gene silencing can be reversed by HDAC inhibitors such as trichostatin-A (TSA). Silent TSGs that cannot be reactivated by 5-AZA-CdR or DZNep have the potential to be reactivated by TSA. This provides a rationale for the use of HDAC inhibitors in combination with 5-AZA-CdR and DZNep to treat AML.

Results: The triple combination of 5-AZA-CdR, DZNep, and TSA induced a remarkable synergistic antineoplastic effect against human AML cells as demonstrated by an in vitro colony assay. This triple combination also showed a potent synergistic activation of several key TSGs as determined by real-time PCR. The triple combination was more effective than the combination of two agents or a single agent. Microarray analysis showed that the triple combination generated remarkable changes in global gene expression.

Conclusions: Our data suggest that it may be possible to design a very effective therapy for AML using agents that target the reversal of the following three epigenetic “lock” mechanisms that silence gene expression: DNA methylation, histone methylation, and histone deacetylation. This approach merits serious consideration for clinical investigation in patients with advanced AML.

Keywords: 5-aza-2'-deoxycytidine, 3-deazaneplanocin-A, Decitabine, Epigenetic therapy, EZH2, Histone deacetylase inhibitors, Myeloid leukemia

* Correspondence: richard.l.momparler@umontreal.ca
1 Département de Pharmacologie, Université de Montréal, 2900 Édouard-Montpetit, Montréal, QC H3T 1J4, Canada
2 Centre de recherche, Service d’hématologie/oncologie, CHU-Saint-Justine, Montréal, Québec H3T 1C5, Canada
Full list of author information is available at the end of the article

© 2014 Momparler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Epigenetic mechanisms that control gene expression play an important role in leukemogenesis [1,2]. Aberrant DNA methylation that silences the expression of tumor suppressor genes (TSGs) occurs frequently in patients with acute myeloid leukemia (AML) and can be used to predict the outcome of therapy [3,4]. The importance of this epigenetic modification is illustrated by the use of the inhibitor of DNA methylation, 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), to treat AML [5-8]. However, most AML patients induced into complete remission with 5-AZA-CdR will relapse, which provides a rationale to search for other agents to use in combination to increase the effectiveness of the therapy.

An attractive target in AML is the histone methyltransferase EZH2 [9], a subunit of the polycomb repressive complex 2 (PRC2). Repression of PRC2 target gene transcription occurs by the trimethylation of histone 3 at lysine 27 (H3K27) to H3K27me3 by EZH2 [10]. Overexpression of EZH2 is frequently observed in AML [11] and can block the differentiation of myeloid cells [12]. Additionally, the ectopic expression of EZH2 in murine hematopoietic cells results in excessive myeloid proliferation in bone marrow [13]. These findings suggest that EZH2 plays an important role in leukemogenesis. Reduction in the level of EZH2 by 3-deazaplanocin-A (DZNep), a competitive inhibitor of S-adenosyl-L-homocysteine hydrolase, inhibits the proliferation of AML cells [14]. There is a cross-talk between DNA and histone methylation [15] in which genes marked by the presence of EZH2 recruit DNMT1 [16] and show a higher frequency of DNA methylation in cancer [17]. These findings provided a rationale for using 5-AZA-CdR in combination with DZNep to treat AML by targeting two different epigenetic gene-silencing mechanisms. We previously reported that the combination of these epigenetic agents had potent antineoplastic interaction against AML cells [18].

In an attempt to optimize this epigenetic therapy of AML, we investigated whether the reversal of a third gene-silencing mechanism would further enhance the anti-leukemic action of 5-AZA-CdR plus DZNep. Epigenetic gene silencing can also be due to the conversion of open chromatin to a compact configuration by histone deacetylase (HDAC). HDAC inhibitors can reverse this block and show potential for the treatment of leukemia [19]. There is also a cross-talk between DNA methylation and HDAC to silence gene expression. The mechanism is due to the attachment of a 5-methylcytosine-binding protein to the target gene promoter, which is followed by the recruitment of HDAC [20]. The importance of this interaction in AML cells is shown by the synergistic activation of the TSG CDKN2B (p15) by 5-AZA-CdR plus the HDAC inhibitor, trichostatin-A (TSA) [21]. 5-AZA-CdR plus HDAC inhibitors show interesting antineoplastic activity against leukemia in both the laboratory [22] and clinic [23].

The cross-talk between DNA methylation, histone methylation, and histone deacetylation provides a rationale for using a combination of epigenetic agents that target these three gene-silencing mechanisms. In this report, we investigated the antineoplastic action of the combination of 5-AZA-CdR, DZNep, and TSA on AML cells. This combination of three epigenetic agents shows remarkable anti-leukemic activity against leukemic cells.

Results
Growth inhibition and reduction in survival of AML cells by combination of epigenetic agents
In previous reports from our laboratory we demonstrated that the antineoplastic activity of 5-AZA-CdR and DZNep or an HDAC inhibitor was synergistic on myeloid leukemia cell lines [18,22]. Our objective was to determine if the triple combination of these agents would be more effective than single or double combinations. The experimental approach was to treat AML cells with 5-AZA-CdR followed by the addition at 24 h of DZNep and TSA using concentrations as indicated in the legends. We used a sequential drug treatment that started with 5-AZA-CdR and was followed by histone modifiers because cell cycle analysis indicates that both DZNep and TSA can inhibit the progression of G1 cells into the S phase [14,19]. Because 5-AZA-CdR is S phase-specific, any block in the transit of the cells into the S phase induced by DZNep or TSA could allow some leukemic stem cells to escape the antineoplastic action of 5-AZA-CdR. At 48 h post drug treatment, the inhibition of cell growth was measured and the leukemic cells were plated in soft agar for colony assay. For both HL-60 (Figure 1A) and AML-3 (Figure 1B) cells, the triple combination produced a significantly greater inhibition of growth than either the single or double agents, except for the combination of DZNep plus TSA, which was not significant.

A colony assay was performed to determine the survival of the leukemic cells produced by each individual agent and the different combinations of these agents. For both HL-60 (Figure 1C) and AML-3 (Figure 1D) cells, the triple combination produced a significantly greater reduction of survival than either the single or double agents. No HL-60 cells survived following treatment with the triple combination, whereas for AML-3 cells, only ≤2% survival was observed. The combination of DZNep plus TSA showed remarkable anti-leukemic activity as indicated by only 7.0% and 7.8% survival for the HL-60 and AML-3 cells, respectively (Figure 1C and D). Single agent treatment alone showed >64% and >45% survival for HL-60 and AML-3 cells, respectively.
Induction of apoptosis on AML cells by combination of epigenetic agents

Since drug resistance can be due to the suppression of apoptosis [24], we investigated the activity of the epigenetic agents alone and in combination on this parameter. DZNep was reported to induce apoptosis in myeloid leukemia cells [14] and tumor cells [25]. The induction of apoptosis by 5-AZA-CdR, DZNep, and TSA on the myeloid leukemia cell lines was evaluated by Annexin V-PI staining (Figure 2). The concentration of these agents and exposure time were identical to that used for the growth and colony assay. For the AML-3 cells, as single agents or 5-AZA-CdR plus DZNep or plus TSA produced less than 15% apoptosis (Figure 2A). The combination of TSA plus DZNep produced 41.7% apoptosis as compared to 76.4% apoptosis by the triple combination, a synergistic interaction for both combinations as compared to the respective single agents or double combinations. The triple combination produced the most potent apoptotic activity. For the HL-60 cells, as single agents 5-AZA-CdR or DZNep produced less than 15%, and TSA alone produced 27.1% apoptosis (Figure 2B). 5-AZA-CdR plus DZNep or 5-AZA-CdR plus TSA produced 17.8% and 23.1% apoptosis, respectively. The TSA plus DZNep combination showed a synergistic induction of apoptosis of 75.8%, whereas the triple combination produced a greater apoptotic activity of 91.3%. For both these combinations the interaction was synergistic as compared to single agents or double combinations.

Figure 1 Growth inhibition assay (A, B) and colony assay (C, D) of leukemic cells after sequential treatment with 5-AZA-CdR (A), DZNep (D), and/or TSA (T). The leukemic cells were treated with 20 nM 5-AZA-CdR and, at 24 h, 500 nM (AML-3) or 1,000 nM (HL-60) DZNep and/or 40 nM (AML-3) or 80 nM (HL-60) nM TSA were added to the medium. At 48 h the cells were counted and placed in soft agar for colony assay to determine growth inhibition and cell survival, respectively. The results are expressed as mean ± SEM, n = 3. Statistical analysis for growth inhibition and reduction in survival: A + D + T > (A + D, A + T) P <0.05 (one way ANOVA).
on the cell cycle of the HL-60 and AML-3 leukemic cells by flow cytometry (Figure 3). Drug concentrations were identical as in Figure 1 and analysis was performed at 48 h. For AML-3 cells, TSA alone increased the fraction of cells in G1/G0 to 55% as compared to 45% for the control and decreased the fraction of cells in the S phase to 18% as compared to the control of 32% (Figure 3A). These data suggest that TSA blocks the progression of G1 cells into the S phase and supports the rationale for sequential treatment of 5-AZA-CdR followed by TSA. For both cell lines, the double combination of DZNep plus TSA and the triple combination produced a remarkable synergistic increase in the fraction of cells in sub-G1 phase (Figure 3A and B). These latter data correlate with the induction of apoptosis by these combinations (Figure 2).

Changes in gene expression in AML cells induced by combination of epigenetic agents
In order to understand some of the molecular changes that take place in the leukemic cells, we analyzed the expression of several target genes that may play a role in leukemogenesis using real-time RT-PCR. For HL-60 cells, the triple combination produced a synergistic activation of the following genes: CDKN1A (p21), FBXO32, CD86, and SPARC (Figure 4). For AML-3 cells, the triple combination produced a synergistic activation of the following genes: CDKN1A (p21), EGR3, FBXO32, CD86, and CDKN2B (p15) (Figure 5). For both cell lines, each agent alone and in double combination produced an increase in expression of these genes that was much less than the triple combination.

For the double combinations on HL-60 cells (Figure 4), the TSA plus DZNep combination showed a synergistic activation for CDKN1A, FBXO32, CD86, and SPARC compared to each agent alone. The 5-AZA-CdR plus TSA combination showed a synergistic activation for SPARC. The 5-AZA-CdR plus DZNep combination showed a synergistic activation for EGR3, CD86, and CDKN2B. For the double combinations on AML-3 cells (Figure 5), the TSA plus DZNep combination showed a synergistic activation for all the genes. The 5-AZA-CdR plus TSA combination showed a synergistic activation for all the genes except CDKN1A. The 5-AZA-CdR plus DZNep combination showed a synergistic activation for only SPARC.

Microarray analysis of AML-3 cells following the treatment with the epigenetic agents was performed on genome-wide gene expression data and focused on the cohort of the top 1,000 genes that showed greatest increase in gene expression by the triple combination (Figure 6). Single agent and double agent treatment showed much less activation of gene expression as compared to triple combination of 5-AZA-CdR and DZNep plus TSA. The combination of DZNep plus TSA showed a remarkable increase in gene expression as compared to each single...
agent and to the other double combinations. The data on microarray are in accord with the results on survival, apoptosis, and gene expression analysis by real-time PCR (Figures 1, 2 and 5). (The complete microarray data are shown in Additional file 1: Table S1).

Reduction in survival of AML cells by a combination of different epigenetic agents

DZNep is reported to be a global histone methyltransferase inhibitor that is not only specific for EZH2 [26]. In order to demonstrate that EZH2 is the primary target of DZNep, we replaced this analogue by GSK-126, a specific inhibitor of EZH2 [27]. For AML-3 cells, the combination of 5-AZA-CdR, GSK-126, and TSA showed a similar synergistic interaction in a colony assay as the triple combination that contained DZNep (Figure 7A). It should be noted that the DZNep plus TSA combination was much more potent than GSK-126 plus TSA. Replacement of TSA by the HDAC inhibitor MS-275 (entinostat) still showed a synergistic interaction for the
triple combination on AML-3 cells in a colony assay (Figure 7B). The DZNep plus MS-275 was less potent than DZNep plus TSA. MS-275 is in clinical trial in patients with AML [28]. The results obtained with the triple combination of 5-Aza-CdR and GSK-126 plus MS-275 on AML-3 (Figure 7C) and HL-60 (Figure 7D) are similar to those in Figure 1.

**Discussion**

There are several possible approaches that can be used to increase the therapeutic efficacy of AML therapy. The first approach is to optimize the dose schedule of 5-AZA-CdR [29,30]. Responses in patients with AML can be obtained with both low [5-8] and high doses of 5-AZA-CdR [31,32]. A second approach is to avoid the development of drug resistance to 5-AZA-CdR. We reported previously that drug resistance to this analogue due to deficiency in deoxycytidine kinase (the enzyme that activates this prodrug) could be overcome with the use of 3-deazauridine [33]. A third approach is to enhance the epigenetic action of 5-AZA-CdR on gene expression by its use in combination with other epigenetic agents.

In AML patients, gene-specific hypomethylation induced by 5-AZA-CdR does not always correlate with mRNA expression or leukemic blast count in bone marrow [34,35]. Genes silenced by DNA methylation may escape reactivation by 5-AZA-CdR if they contain the repressive marker, H3K27me3 [36]. If after 5-AZA-CdR treatment, the H3K27me3 mark is not removed, it can serve as a nidus for DNA re-methylation and gene silencing [36,37]. This removal of the H3K27me3 mark can be accomplished by the use of DZNep. The advantages of using DZNep in combination with 5-AZA-CdR...
are three fold. First, DZNep can reduce the H3K27me3 gene-silencing mark to activate the expression of genes that are demethylated, but not activated, by 5-AZA-CdR [36]. Second, DZNep can activate the expression of a unique cohort of genes compared to 5-AZA-CdR [38]. In both cases, a substantial number of genes are reacti-vated by the combination more so than either agent alone, resulting in greater anti-leukemic activity. Third, this combination of epigenetic agents can target the reactivation of genes that program cellular differentiation [12]. Our previous report shows that DZNep interacts synergistically with 5-AZA-CdR to activate gene expres-sion and reduce leukemic cell survival [18]. This interesting drug interaction can be explained in part by the reversal of the “double lock” epigenetic mechanism for gene silencing by DNA and histone methylation.

Some investigators state that DZNep is not an ideal agent for targeted therapy because it is a global inhibitor of histone methyltransferases and is not specific for EZH2 [26]. However, it should be noted that DZNep shows potent antineoplastic activity against AML cells [14,18]. In support of EZH2 as a target for DZNep is our observation that replacement of this analogue by the specific inhibitor of EZH2, GSK-126 [27], provides similar results with respect to its interaction with 5-AZA-CdR on AML cells (Figure 7A). Overexpression of EZH2 in myeloid malignancies suggests that it functions as an oncogene [39]. However, loss-of-function mutations in EZH2 indicate that it may also function as a TSG in leukemia [39]. In the latter case, EZH2 inhibitors alone may not be appropriate agents for treating leukemia with this genetic abnormality. This question can be resolved by in vitro colony assays to test the sensitivity to DZNep of AML cells with EZH2 loss-of-function mutations. It should be noted that the action of 5-AZA-CdR and HDAC inhibitors may abolish the oncogenic potential of

![Figure 5](image-url)
EZH2 inhibitors when used in combination. More studies are required to clarify the role of EZH2 mutations in the therapy of hematologic malignancies.

Another epigenetic mechanism of gene silencing is the conversion of open chromatin to a compact configuration by the action of HDAC. Its importance is illustrated by the positive interaction of 5-AZA-CdR with HDAC inhibitors to reactivate silent TSGs [21] and to inhibit the growth of leukemic cells [22]. Clinical trials on 5-AZA-CdR in combination with the HDAC inhibitor, valproic acid, was shown to induce complete response in some patients with AML [23,40]. There are also advantages to use HDAC inhibitors in combination with 5-AZA-CdR to treat AML. 5-AZA-CdR treatment only demethylates approximately half of the genes that are silenced by the presence of 5-methylcytosines in their promoter region [36,41]. This indicates that 5-AZA-CdR has a limited capacity to reactivate all silent TSGs and some leukemic stem cells escape its therapeutic action. It is important to note that HDAC inhibitors, as single agents in some cases, can activate genes silenced by DNA methylation [41]. Because the combination of HDAC inhibitors with 5-AZA-CdR has the potential to reactivate more silent TSGs than either agent alone, this will result in a marked enhancement of its anti-leukemic action. Our data are in accordance with this statement (Figure 1 and 7).

The triple combination of different epigenetic agents merits investigation in patients with advanced AML. This will require the approval of DZNep for clinical trials. TSA can be replaced by MS-275 (entinostat), an HDAC inhibitor that is approved for clinical studies and that shows some activity in patients with AML [28]. MS-275 had an interaction with 5-AZA-CdR that was similar to TSA with respect to the survival of leukemic cells (Figure 7B). Additionally, the combination of 5-AZA-CdR, GSK-126, and MS-275 also had a synergistic interaction against AML-3 (Figure 7C) and HL-60 cells (Figure 7D).

Curative therapy for AML requires the complete eradication of the proliferative potential of a very large number of leukemic stem cells. Leukemic cells containing TSGs silenced by more than one epigenetic mechanism may have the potential to escape 5-AZA-CdR therapy. The chemotherapeutic action of 5-AZA-CdR may be related not only to the reactivation of specific TSGs, but it may also be dependent on the total number of genes reactivated. This goal can be achieved by the use of a combination of agents that reverse the “triple lock” epigenetic silencing mechanisms: DNA methylation, histone methylation, and deacetylation. It should be noted that each of these agents activates different cohorts of genes with minimal overlap [18,38]. We show that targeting the “triple lock” epigenetic silencing mechanisms by the combination of 5-AZA-CdR, DZNep, and TSA has a remarkable synergistic antineoplastic interaction on AML cells. The combination of these three epigenetic agents showed a synergistic reduction in the survival of AML cells as determined by a colony assay that was greater than observed with either single or double agent treatment (Figure 1). Additionally, the
triple combination showed a remarkable synergistic induction of apoptosis in the AML cells (Figure 2). Resistance to the induction of apoptosis by chemotherapy is one of the hallmarks of cancer and can allow for the survival of malignant cells following drug treatment [24].

The notable changes in gene expression following the treatment of AML cells with the three epigenetic agents is most likely the major mechanism responsible for its chemotherapeutic action. Quantitative real-time PCR showed a remarkable synergistic reactivation by the triple combination of several genes: CDKN1A (p21), EGR3, FBXO32, CD86, SPARC, and CDKN2B (p15), which correlated with its antineoplastic action (Figures 4 and 5). All of these genes have some relationship with leukemogenesis [14,42-47]. The cyclin-dependent kinase inhibitor, CDKN2B (p15), is frequently silenced by DNA methylation in AML [42]. In conclusion, the reversal of the "triple lock" mechanism of epigenetic gene silencing with specific agents that target DNA methylation, histone methylation, and deacetylation holds great promise for the treatment of AML. This combination therapy can reverse the key epigenetic aberrations that take place during leukemogenesis, and it has the capacity to eradicate the proliferative potential of leukemic stem cells. Additional research will clarify the importance of this interesting epigenetic therapy and define its future role in the therapy of AML.

Conclusions

In conclusion, the reversal of the "triple lock" mechanism of epigenetic gene silencing with specific agents that target DNA methylation, histone methylation, and deacetylation holds great promise for the treatment of AML. This combination therapy can reverse the key epigenetic aberrations that take place during leukemogenesis, and it has the capacity to eradicate the proliferative potential of leukemic stem cells. Additional research will clarify the importance of this interesting epigenetic therapy and define its future role in the therapy of AML.
Methods

Cell lines and materials

HL-60 and OCI-AML-3 human myeloid leukemic cells were obtained from ATCC and Dr Mark Minden, Ontario Cancer Institute, Toronto, respectively. The HL-60 and AML-3 cells were maintained in RPMI-1640-HEPES media and alpha-MEM (GIBCO), respectively. Fetal bovine serum (Wisent) was added to these media at a final concentration of 10%. 5-AZA-CdR was obtained from Dr Alois Piskala, Institute of Organic Chemistry, Czechoslovak Academy of Sciences, Prague. DZNep was kindly provided by Dr Victor E. Marquez, Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA. 5-AZA-CdR and DZNep were dissolved in sterile phosphate buffer saline (PBS) pH 6.8 solution. TSA was acquired from Sigma and dissolved in ethanol. GSK-126 was obtained from Xcess Biosciences Inc. and dissolved in DMSO. MS-275 (entinostat) was provided by Schering (Germany) and dissolved in ethanol.

Growth inhibition and colony assay

The HL-60 and AML-3 cells were treated with the indicated concentrations of drugs. Following the drug treatment, a cell count was performed using the Beckmann Model Z Coulter Counter. For colony assay, the cells were placed in 0.3% soft agar medium containing 20% fetal bovine serum (Wisent) was added to these media at a final concentration of 10%. 5-AZA-CdR was provided by Schering (Germany) and dissolved in ethanol.

Apoptosis analysis

Annexin V and propidium iodide (PI) staining were used to assess apoptosis and was determined using flow cytometry. The cells were treated as indicated. Twenty-four hours after the end of drug treatment, the cells were washed twice with cold PBS and resuspended in 1X Annexin V binding buffer (BD Biosciences Pharmingen). Then, 2 x 10^5 cells were mixed gently with Annexin V-FITC (BD Biosciences Pharmingen) and PI solution (Sigma-Aldrich), and incubated for 15 min in the dark at room temperature. The cells were suspended in 1X Annexin V binding buffer and staining was immediately quantified using a BD LSR Fortessa flow cytometer (San Jose, CA, USA), and analyzed with the BD DIVA (San Jose, CA, USA) software program. A minimum of 10,000 cells within the gated region was analyzed per measurement.

Cell cycle analysis

The cells were treated as indicated. After 48 h treatment, 4 x 10^6 cells were washed twice with cold PBS containing 1% FBS. After ethanol fixation (at least 12 h at 4°C), cells were washed twice with cold PBS. The pelleted cells were stained by adding PBS containing PI (Sigma-Aldrich) and RNase A (Amersham). Staining was achieved in the dark at 4°C for 3 h prior to flow cytometry analysis using a BD LSR Fortessa flow cytometer, and analyzed with the Tree Star FlowJo (Ashland, OR, USA) software program to model the cell cycle assays. Fluorescence data were collected using a 561 nm laser excitation, and emission was collected using a 610/20 filter. Fluorescence data were obtained from at least 10,000 viable cells per sample.

Analysis of gene expression

For quantitative PCR analysis, total RNA was reversed transcribed using the High Capacity cDNA Reverse Transcription Kit with random primers as described by the manufacturer (Applied Biosystems). The reaction mixture contained cDNA, specific primers for the target genes, Sybr green and TaqMan Fast Universal PCR Master Mix (Applied Biosystems). The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used to detect the amplification level. All reactions were run in triplicate and the average Cts were used for quantitation. The endogenous control was the TATA-binding protein (TBP) gene. The relative quantification of the target genes was determined using the ΔΔCT method. (The primers used for PCR analysis are shown in Additional file 1: Table S1).

For microarray analysis of gene expression, at 24 h after the end of drug treatment, total RNA was isolated from AML-3 cells using the RNAeasy Mini kit (Qiagen). Reverse transcription was performed using the Total Prep RNA Amplification kit (Ambion). The cDNA synthesis and in vitro transcription amplification were followed by microarray hybridization using the Human HT-12 v.4.0 Expression BeadChip kit following the manufacturer recommended protocols (Illumina). Three samples were replicated and all clustered adjacent to one another and the expression intensities were averaged in the statistical analysis. The raw intensities were extracted with the gene expression module in Illumina’s BeadStudio software. Expression intensities were log2 transformed and quantile normalized. A total of 30,442 with expression above background levels were retained for further analyses. Statistical analysis was performed using SAS 9.3 and JMP Genomics 6.1. Clustering analysis was done using the Ward method.

Additional files

Additional file 1: Table S1. Excel file of gene expression by microarray analysis.

Additional file 2: Table S2. Sequence of primers used for real-time PCR analysis.

Abbreviations

AML: Acute myeloid leukemia; 5-AZA-CdR: 5-aza-2'-deoxycytidine; DZNep: 3-deazaneplanocin-A; TSA: Trichostatin-A; TSG: Tumor suppressor gene.

Competing interests

The authors declare that they have no competing interests.
Authors’ contributions
RLM and SC designed the research, SC and LFM performed the experimental work. RLM and SC collected, analyzed, interpreted the data, and wrote the manuscript. YL analyzed and interpreted the microarray data. The manuscript was approved by all the co-authors.

Acknowledgements
This research was funded by the Canadian Cancer Society (grant #700795). We thank Ms. Nadine Fradet and Ms. Julie Lafontaine, Institute for Research in Immunology and Cancer, Université de Montréal, for assistance in real-time PCR analysis, and Mr. Christian Young, Lady Davis Institute Flow Cytometry and Cell Imaging Facility, Montreal, for assistance in cell cycle analysis.

Author details
1Département de Pharmacologie, Université de Montréal, 2900 Édouard-Montpetit, Montréal, QC H3T 1J4, Canada. 2Centre de recherche, Service d’hémato-oncologie, CHU-Saint-Justine, Montréal, Québec. H3T 1C5, Canada. 3Department of Biology, New York University, Saadyat Island, PO Box 129188, Abu Dhabi, United Arab Emirates.

Received: 9 June 2014 Accepted: 18 September 2014
Published: 1 October 2014

References
1. Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358:1184–1159.
2. Baylin SB, Jones PA: A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011, 11:726–734.
3. Figueroa ME, Lugthart S, Li Y, Erpelnick-Verschueren C, Deng X, Christos PJ, Schianno E, Booth J, van Putten W, Sbranaké L, Campagne F, Mazumdr M, Greally JM, Valk PJ, Löwenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13–17.
4. Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, Gaidzik V, Christiansen J, Eriksen PM, Sebjørg L, Landgren O, Schiødtova B, Hansen KD, Goldstone AH, Dohner K, Cairoli R, Döhner K, Hagemeijer A, Wijermans PW, Döhner K: Decitabine for the first-line treatment of older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Blood 2009, 113:659–664.
5. Issa JP, Garcia-Manero G, Giles FJ, Mamari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J: A phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (Zadecitabine) in hematopoietic malignancies. Blood 2004, 103:1635–1640.
6. Cashen AF, Schiller JG, D’Orellanni MR, DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556–561.
7. Plum W, Ganzer R, Klosow RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalon-Calero M, Croce CM, Marcucci G: Clinical response and min-M29 predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010, 107:7473–7478.
8. Lubbret M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Momparler RL, Côté S, Eliopoulos N, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL: Enhancement of antineoplastic action of 5-aza-2’-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leukemia Lymphoma 2004, 45:147–154.
9. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Ventsoviek S, Ryttng M, Wiera GD, Radvani F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, Obricens S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP: Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271–3279.
10. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 2011, 144:646–664.
11. Tan J, Yang X, Zhong L, Jiang X, Chen W, Lee PL, Karutzi RK, Tan PB, Liu ET, Yu Q: Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Gene Dev 2007, 21:1050–1063.
12. Miranda TB, Cortez CC, Yoo CB, Liang G, Ape M, Kelly TK, Marquez VE, Jones PA: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cell 2009, 33:1579–1588.
13. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Delta Pietra A III, Diao E, Lafiitance LV, Mellingor M, Duquennoe C, Tian X, Kuoger RG, McHugh CF, Brands M, Miller WH, Danan D, Verma SK, Tummino PJ, Creasy CL: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108–112.
14. Gojo I, Jiemij A, Trepel JB, Sarebrooin A, Figg WD, Rolllins S, Sidwell MW, Geer J, Chung EL, Lee MJ, Gore SD, Sauvile EA, Zwiebel I, Karp JM: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemia. Blood 2007, 109:2760–2769.
15. Momparler RL, Côte S, Eliopoulos N: Pharmacological approach for optimization of the dose-schedule of 5-aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 1997, 11:175–180.
16. Lemaire M, Chabot GD, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL: Importance of dose-schedule of 5-aza-2’-deoxycytidine for the epigenetic therapy of cancer. BMC Cancer 2008, 8:126.
17. Momparler RL, Ravid GE, Geyer S, Puleo M: Clinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemia. Pharmac Ther 1986, 30:277–286.
18. Redl JL, Colly LP, Klin-Nellemans JC, Willemse R: The antileukaemic activity of 5-aza-2’-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer 1991, 64:144–148.
19. Raynal NJ, Momparler LF, Ravid GE, Momparler RL: 3-Deazauridine enhances the antileukemic action of 5-aza-2’-deoxycytidine and targets
drug-resistance due to deficiency in deoxycytidine kinase. *Leuk Res* 2010, 35:110–118.

34. Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lübbert M: Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. *Leuk Res* 2013, 37:190–196.

35. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curlman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschi R, Marcucci G. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. *Blood* 2012, 120:2466–2474.

36. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP: Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. *Cancer Res* 2010, 70:6968–6977.

37. McGarvey KM, Fahmer JA, Greene E, Martens J, Jenuwein T, Baylin SB: Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. *Cancer Res* 2006, 66:3541–3549.

38. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q: Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. *Mol Cancer Ther* 2009, 8:3191–3202.

39. Lund K, Adams PD, Copland M: EZH2 in normal and malignant hematopoiesis. *Leukemia* 2014, 28:44–49.

40. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Heerema NA, Murgo A, Chain KK, Grever MR, Byrd JC, Marucci G: Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. *J Clin Oncol* 2007, 25:3884–3891.

41. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP: DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. *Cancer Res* 2012, 72:1170–1181.

42. Agrawal S, Unterberg M, Koschmieder S, Zur Stadt U, Brunnberg U, Verbeek W, Bücher T, Berdel WE, Serve H, Müller-Tidow C: DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. *Cancer Res* 2007, 67:1370–1377.

43. Paul TA, Bies J, Wolff L: Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. *Blood* 2010, 115:3101–3107.

44. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuwa H, Matsuoika M: Identification of aberrantly methylated genes in association with adult T-cell leukemia. *Cancer Res* 2004, 64:6002–6009.

45. Re F, Arpinati M, Testoni N, Ricci P, Terragna C, Preda P, Ruggeri D, Senese B, Chirumbolo G, Martelli V, Urtbaiti B, Baccarani M, Tura S, Rondelli D: Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. *Exp Hematol* 2002, 30:126–134.

46. Galliongò C, La Cava P, Tibil G, Barbargallo L, Paninnello N, Cupri A, Stagn F, Consoli C, Chiaremi A, Pulumbo GA, Di Raimondo F: SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. *BMC Cancer* 2013, 13:60.

47. Gartel AL: P21(WAF1/CIP1) may be a tumor suppressor after all. *Cancer Biol Ther* 2007, 6:1171–1172.